Detailed Information on Publication Record

PLEVA, Leos, Pavel KUKLA and Ota HLINOMAZ. Treatment of coronary in-stent restenosis: a systematic review. Journal of Geriatric Cardiology. Beijing: Science Press, 2018, vol. 15, No 2, p. 173-184. ISSN 1671-5411. Available from: https://dx.doi.org/10.11909/j.issn.1671-5411.2018.02.007.

Other formats: BibTeX LaTeX RIS

Basic information
Original name	Treatment of coronary in-stent restenosis: a systematic review
Authors	PLEVA, Leos (203 Czech Republic, guarantor), Pavel KUKLA (203 Czech Republic) and Ota HLINOMAZ (203 Czech Republic, belonging to the institution).
Edition	Journal of Geriatric Cardiology, Beijing, Science Press, 2018, 1671-5411.

Other information
Original language	English
Type of outcome	Article in a journal
Field of Study	30201 Cardiac and Cardiovascular systems
Country of publisher	China
Confidentiality degree	is not subject to a state or trade secret
Impact factor	Impact factor: 1.763
RIV identification code	RIV/00216224:14110/18:00104044
Organization unit	Faculty of Medicine
Doi	http://dx.doi.org/10.11909/j.issn.1671-5411.2018.02.007
UT WoS	000429624200007
Keywords in English	Drug-eluting balloon; Drug-eluting stent; In-stent restenosis
Tags	14110115, rivok
Tags	International impact, Reviewed
Changed by	Changed by: Soňa Böhmová, učo 232884. Changed: 11/2/2019 15:38.

Abstract
Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. ISR after coronary angioplasty is currently one of the main limitations of this method, leading to the recurrence of exertional angina pectoris or acute coronary syndromes. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%-10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. We undertook a systematic review of the pathophysiology, diagnostics and treatment options for BMS- and DES-ISR. We discuss recent randomised studies, comparing different DES or DEB used for BMS or DES-ISR treatment, as well as the use of new biovascular scafolds and the topic of scafold restenosis.

Abstract

Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. ISR after coronary angioplasty is currently one of the main limitations of this method, leading to the recurrence of exertional angina pectoris or acute coronary syndromes. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%-10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. We undertook a systematic review of the pathophysiology, diagnostics and treatment options for BMS- and DES-ISR. We discuss recent randomised studies, comparing different DES or DEB used for BMS or DES-ISR treatment, as well as the use of new biovascular scafolds and the topic of scafold restenosis.